Provided by Tiger Trade Technology Pte. Ltd.

Eupraxia Pharmaceuticals

7.83
-1.2700-13.96%
Post-market: 7.61-0.2200-2.81%19:30 EDT
Volume:3.65M
Turnover:29.37M
Market Cap:517.35M
PE:-7.86
High:9.12
Open:8.91
Low:7.68
Close:9.10
52wk High:9.32
52wk Low:5.25
Shares:66.07M
Float Shares:56.79M
Volume Ratio:4.49
T/O Rate:6.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9967
EPS(LYR):-1.0300
ROE:-66.70%
ROA:-43.66%
PB:5.08
PE(LYR):-7.60

Loading ...

Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth

GlobeNewswire
·
Jul 14

Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization

GlobeNewswire
·
Jul 07

Eupraxia Pharmaceuticals Initiated at Outperform by Oppenheimer

Dow Jones
·
Jun 26

Eupraxia Pharmaceuticals initiated with an Outperform at Oppenheimer

TIPRANKS
·
Jun 26

Eupraxia Pharmaceuticals Shareholders Back Board Slate and Auditor at June 18 AGM

TIPRANKS
·
Jun 22

Eupraxia Pharmaceuticals Sets June 18, 2026 Virtual AGM and Files May Form 6-K

TIPRANKS
·
May 30

Eupraxia Pharmaceuticals Confirms Mailing of 2026 Proxy Materials to Shareholders

TIPRANKS
·
May 30

Eupraxia Pharmaceuticals to Showcase Pipeline at Jefferies Global Healthcare Conference

TIPRANKS
·
May 29

Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

GlobeNewswire
·
May 28

Stifel Initiates Eupraxia Pharmaceuticals at Buy With CA$34.37 Price Target

MT Newswires Live
·
May 21

Eupraxia Pharmaceuticals Inc : Stifel Initiates Coverage With Buy Rating; Target Price $25

THOMSON REUTERS
·
May 21

Eupraxia Pharmaceuticals initiated with a Buy at Stifel

TIPRANKS
·
May 21

Eupraxia Pharmaceuticals Reports Stronger Balance Sheet but Wider Q1 2026 Loss in Form 6-K Filing

TIPRANKS
·
May 13

Eupraxia Pharmaceuticals reports Q1 net loss ($12.7M) vs. ($6.8M) last year

TIPRANKS
·
May 13

Eupraxia Pharmaceuticals Q1 EPS $(0.23) Misses $(0.22) Estimate

Benzinga Earnings
·
May 13

Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results

GlobeNewswire
·
May 13

Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)

GlobeNewswire
·
May 05

Eupraxia Pharmaceuticals Price Target Maintained With a $11.00/Share by HC Wainwright & Co.

Dow Jones
·
May 05

H.C. Wainwright Remains a Buy on Eupraxia Pharmaceuticals (EPRX)

TIPRANKS
·
May 04

Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer

GlobeNewswire
·
May 02